Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
November 6, 2023
This article is featured on another website.
Go to article
May 20, 2026
The Medicine Maker – Rethinking Progress in Clinical Trials
May 20, 2026
The Medicine Maker – Rethinking Progress in Clinical Trials
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…